Eton Pharmaceuticals Inc (ETON, Financial) is set to release its Q3 2024 earnings on Nov 12, 2024. The consensus estimate for Q3 2024 revenue is $9.70 million, and the earnings are expected to come in at -$0.01 per share. The full year 2024's revenue is expected to be $37.11 million and the earnings are expected to be -$0.18 per share. More detailed estimate data can be found on the Forecast page.
Eton Pharmaceuticals Inc (ETON, Financial) Estimates Trends
Revenue estimates for Eton Pharmaceuticals Inc (ETON) for the full year 2024 have increased from $36.50 million to $37.11 million over the past 90 days. For 2025, revenue estimates have risen from $47.40 million to $67.80 million. Earnings estimates for the full year 2024 have declined from -$0.15 per share to -$0.18 per share, while for 2025, earnings estimates have increased from $0.22 per share to $0.53 per share.
Eton Pharmaceuticals Inc (ETON, Financial) Reported History
In the previous quarter of 2024-06-30, Eton Pharmaceuticals Inc's (ETON) actual revenue was $9.07 million, which beat analysts' revenue expectations of $8.80 million by 3.11%. Eton Pharmaceuticals Inc's (ETON) actual earnings were -$0.12 per share, which missed analysts' earnings expectations of -$0.07 per share by -71.43%. After releasing the results, Eton Pharmaceuticals Inc (ETON) was up by 2.76% in one day.
Eton Pharmaceuticals Inc (ETON, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 2 analysts, the average target price for Eton Pharmaceuticals Inc (ETON) is $13 with a high estimate of $15 and a low estimate of $11. The average target implies an upside of 48.06% from the current price of $8.78.
Based on GuruFocus estimates, the estimated GF Value for Eton Pharmaceuticals Inc (ETON, Financial) in one year is $10.43, suggesting an upside of 18.79% from the current price of $8.78.
Based on the consensus recommendation from 2 brokerage firms, Eton Pharmaceuticals Inc's (ETON, Financial) average brokerage recommendation is currently 2.0, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
